SCHEMBL1912975

SCHEMBL1912975

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccccc1)Cc1cc(OC)cc(OC)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.49
MAPK1 P28482 1/20 0.49
C5AR1 P21730 1/20 0.44
NR1H3 Q13133 2/20 0.37
NR1H2 P55055 1/20 0.37
MAPT P10636 2/20 0.37
TLR7 Q9NYK1 2/20 0.37
ALDH1A1 P00352 3/20 0.36
NPSR1 Q6W5P4 2/20 0.36
KDM4E B2RXH2 2/20 0.36
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36
CRHR1 P34998 2/20 0.36
ADORA3 P0DMS8 1/20 0.36
HPGD P15428 2/20 0.36
TP53 P04637 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36
HSP90AA1 P07900 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL649782 0.93 C5AR1 (0.44) TSHRMAPK1C5AR1NR1H3MAPT
SCHEMBL5135433 0.93 C5AR1 (0.46) TSHRMAPK1C5AR1NR1H3NR1H2
SCHEMBL5072205 0.92 C5AR1 (0.46) TSHRC5AR1MAPTALDH1A1NPSR1
SCHEMBL651365 0.91 C5AR1 (0.46) TSHRC5AR1MAPTALDH1A1NPSR1
SCHEMBL5147943 0.91 C5AR1 (0.43) TSHRMAPK1C5AR1NR1H3ALDH1A1
SCHEMBL648419 0.91 C5AR1 (0.46) TSHRMAPK1C5AR1NR1H3NR1H2
SCHEMBL5137023 0.91 C5AR1 (0.42) TSHRMAPK1C5AR1NR1H3NR1H2
SCHEMBL649941 0.90 C5AR1 (0.41) TSHRMAPK1C5AR1CRHR1SMN1; SMN2
SCHEMBL648977 0.90 C5AR1 (0.41) TSHRMAPK1C5AR1NR1H3MAPT
SCHEMBL651094 0.89 TSHR (0.50) TSHRMAPK1C5AR1NR1H3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed